Encephalopathy is emerging as a recurrent complication of COVID-19 yet remains poorly characterized. We report the case of a middle-aged woman with COVID-19-related encephalopathy presenting as expressive aphasia and inattentiveness, subsequently progressing to agitation and marked confusion. Brain MRI and CSF analysis were unremarkable, while EEG showed slowing with frontal sharp waves. Neuropsychiatric symptoms resolved following treatment with tocilizumab. CNS involvement in COVID-19 may present as a subacute encephalopathy characterized by prominent frontal lobe dysfunction, with language disturbances as first neurological manifestation. Future studies should further investigate the role of tocilizumab in treating COVID-19-related encephalopathy.

中文翻译：

---

托珠单抗治疗后出现失语症缓解的 COVID-19 相关脑病

脑病正在成为 COVID-19 的一种复发性并发症，但其特征仍然很差。我们报告了一例患有 COVID-19 相关脑病的中年妇女，表现为表达性失语和注意力不集中，随后发展为激动和明显的意识模糊。脑部 MRI 和 CSF 分析无异常，而脑电图显示额叶尖波减慢。托珠单抗治疗后神经精神症状消失。COVID-19 的 CNS 受累可能表现为亚急性脑病，其特征是突出的额叶功能障碍，语言障碍是首要的神经系统表现。未来的研究应进一步研究托珠单抗在治疗 COVID-19 相关脑病中的作用。